Oral weight loss drug orforglipron could replace Ozempic, Wegovy if approved
GLP-1 weight loss pill development
FOX News Senior Medical Analyst Marc Siegel, Developments in weight loss drugs, security concerns surrounding the nicotine patches and FDA commissioner. Marty Makary is discussing his interview with the vaccine protocol.
NEWNow you can listen to FOX News articles!
Oral weight loss pill is positioned as a potential alternative to injected GLP-1 drugs such as Özempic and Wegovy, performing well in clinical studies.
According to a press release, the Eli Lilly medication, called the orientalpron, showed “significant weight loss” and cardiometabolic improvements.
The Phase 3 ACADED-1 study published in the Journal of Medical Journal of New England evaluated the safety and effectiveness of the drug in adults with weight-related medical problems and without diabetes.
Weight loss drugs can add years to the lives of Americans, researchers project
He was treated for 72 weeks with three different doses (6 mg, 12 mg and 36 mg) with the participants.
After the trial period, the results showed that Orborglpron meets the primary end point of “reducing superior body weight” compared to a placebo.
The study shows that the new GLP-1 pill can replace injectable drugs for weight loss. (Istock)
The highest dose lost 27.3 pounds on average. Approximately 60% of these participants lost 10% of their body weight, 39.6% lost at least 15%.
The researchers reached almost normal blood sugar levels compared to 42% of the placebo area from 1,127 participants who were pre -diabetes at the beginning of the study.
Clinically “clinically significant improvements” in cardiovascular risk factors associated with obesity, such as orphoria, non -HDL cholesterol, systolic blood pressure and triglycerides.
Popular weight loss drugs can alleviate painful arthritis symptoms, doctors report
The highest dose also reduced a marker for an inflammation called high-precision C-reactive protein by 47.7%.
The study found that the safety profile of the drug is consistent with existing GLP-1 drugs. The most common side effects were gastrointestinals, including slightly moderate nausea, constipation, diarrhea and vomiting.
Participants, who received the highest dose, lost an average of 27.7 kilos after use for one year. (Istock)
Wharton Medical Clinic Director and Canada’s chief working writer MD Sean Wharton wrote that obesity is “complex, global health difficulties” that requires “effective and easy -to -integrated” treatment options “.
‘Next Özempic’ aims to provide 30% weight loss with less side effects
In the press release, “In this phase 3 work, orphhethrpron strengthened the primary treatment potential in primary maintenance by showing strong activity results and security with the GLP-1 class.” He said.
“Obasyon can help reduce the known cardiovascular risk markers associated with obesity and support meaningful improvements in public health.”
Eli Lilly and Company World Center Indianapolis is located in Indiana, Indiana. (Istock)
Lilly, as an obesity medicine, announced that it is progressing with plans to get approval for orphochlpron. The company expects the green light to get it early as 2026. In the same year, he plans to apply for approval to use the drug for Type 2 diabetes treatment.
According to Wall Street analysts, Reuters reported that this pill can be “quickly monitored” in a two -month review process initiated by the Food and Pharmaceutical Administration.
Click here to get the Fox News app
“Analysts, expensively injectable weight loss drugs, the increasing cost burden and the fact that Lilly expanded US production-Trump management, considering the prioritizing problems, the drug is a applicable candidate.”
Click here to sign up for our health bulletin
In an interview with Fox News Digital, MD Sue Decotiis, a medical weight loss doctor in New York, called a “positive addition to arming”, which is cheaper and cheaper for the consumer to produce this medicine.
However, decotiis said that weight loss results were not as “impressive” as much as injected results such as ÖZEMPIC and Mounjaro.
A weight-loss doctor says the injectable GLP-1 results are more impressive than the pill. (Istock)
“However, the compliance with the orientalpron may be better because it is an oral drug,” he said.
According to Decotiis, a concern of this new drug is that there is no peptide with a high safety factor and is “easy to metabolize and adapt to the body.
For more health articles, visit www.foxNews.com/health.
“There may be long -term results that we don’t know yet.” He continued: “I believe that there will be more oral weight loss drugs on the pipeline and I hope they will be in the peptide category.”
Fox News reached Lilly for Digital comment.
